Oxidative Stress and Ventricular Arrhythmia in CS
for predicting cardiovascular death after corticosteroid therapy in patients with active CS. 11 Mc Ardle et al 12 found that, on PET, 18 F-FDG accumulation in the heart tended to be strongest in CS patients with VT than in those with complete atrioventricular block or no arrhythmia. Blankstein et al 13 also reported that, in patients with suspected CS, high-risk cardiac events (death and VT) were significantly associated with abnormal accumulation of 18 F-FDG in cardiac tissues (detected on PET/CT) and with cardiac perfusion defects (detected by rubidium-82 scintigraphy). These findings strongly suggest that inflammation in the heart is closely associated with ventricular arrhythmia.
The aim of the present study was to investigate whether myocardial oxidative stress, as indicated by U-8-OHdG levels, was associated with sustained VT in patients with CS.
Methods
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The authors declare that all supporting data are available within the article and its online supplementary file.
Patients and Study Design
The study protocol is shown in Figure 1 . Sixty-two consecutive patients diagnosed with CS (New York Heart Association class I or II) at our institution between June 2008 and May 2017 were enrolled in this prospective study. CS was defined as active (active CS group, n=36) or nonactive (nonactive CS group, n=26) according to the presence or absence of abnormal 18 F-FDG accumulation in the heart on PET/CT. The 36 active patients with CS were further subdivided into CS with VT (CS-VT) and CS without VT (CS-nVT) groups. VT was defined as sustained VT (VT exceeding 100 bpm and 30-s duration) and electrical storm (>3 documented episodes of VT within 24 hours). CS-VT patients had at least 1 documented episode of sustained VT before admission. A cohort of patients diagnosed with idiopathic DCM served as HF controls (n=27). Furthermore, patients with active pulmonary sarcoidosis, diagnosed based on histological findings or 18 F-FDG PET accumulation, were used as inflammatory controls.
Patients with acute HF, acute coronary syndrome, cancer, systemic inflammatory diseases such as infection or collagen disease, severe renal disease (estimated glomerular filtration rate <30 mL·min·1.73 m 2 ), or who smoked tobacco were excluded. CS was diagnosed according to the criteria of the Japanese Ministry of Health and Welfare, revised in 2006 (Table I in the Data Supplement). 14, 15 The Institutional Review Board of Yamaguchi University Hospital approved this study (H19-87) on April 16, 2008 , and all patients provided written informed consent before participating.
Standard Clinical Evaluation
All patients underwent 12-lead ECG, echocardiography, and 18 F-FDG PET/CT (or 67 Ga scintigraphy). All patients were monitored by Holter ECG or by an ECG monitor (Nihon Kohden, Tokyo) or implantable device (implantable cardioverter-defibrillator, cardiac resynchronization therapy defibrillator, or dual-chamber pacemaker). Twenty-four of the 36 patients with active CS underwent endomyocardial biopsy.
Evaluation of Inflammation Using

18
F-FDG PET/CT
All patients underwent 18 F-FDG PET/CT examination with a 16-slice hybrid PET/CT scanner (Gemini GXL16, Philips Medical System) with whole-body and cardiac acquisitions as described previously. 10, 11 Quantitative analysis of 18 F-FDG uptake in the lesion was based on the maximum standardized uptake (SUVmax) value per focus, as described previously.
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Echocardiographic Regional Wall Motion Abnormality Score as a Marker of Myocardial Scar
All patients underwent 2-dimensional transthoracic echocardiography. Echocardiographic images (2-dimensional standard views) were acquired and interpreted by 2 independent blinded observers. In case of disagreement, a third observer interpreted the images. Regional wall motion abnormality score on echocardiography was assessed as the wall motion score based on a standard 17-segment model with numeric scores for contractile function as follows: (1) normal contraction; (2) mild hypokinesis; (3) severe hypokinesis; (4) akinesis; and (5) dyskinesis. 16 
Measurement of 8-OHdG and Other Neurohumoral and Inflammatory Factors
Serum and U-8-OHdG concentrations were measured using an enzyme-linked immunosorbent assay kit (Japan Institute for the Control of Aging, Fukuroi, Japan) with anti-8-OHdG antibody (N45.1), as described previously. [8] [9] [10] [11] Other neurohumoral and inflammatory factors were measured as described previously.
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Histology and Immunohistochemical Examination
Immunohistochemical examination of 8-OHdG was performed in endomyocardial biopsy samples from 58 patients (24 active CS, 13 nonactive CS, and 21 DCM) and 3 control subjects who had normal cardiac function and idiopathic VT, according to a previously described Figure 1 . Study design. The 62 CS patients were divided into 2 groups based on the accumulation of 18 F-FDG in the heart: active CS (n=36) and nonactive CS (n=26). The active CS patients were further divided into CS-VT (n=18) and CS-nVT groups (n=18). Twenty-seven patients diagnosed with DCM were used as heart failure controls. The relationship between sustained VT and the determining factors was examined. CS-VT indicates cardiac sarcoidosis with ventricular tachycardia; CS-nVT, cardiac sarcoidosis without ventricular tachycardia; and DCM, dilated cardiomyopathy.
protocol, with a slight modification. 10 In each patient, 3 endomyocardial biopsy samples were taken from 3 different portions of the left ventricle (LV), from site-directed areas where 18 F-FDG accumulation seemed highest. These samples were fixed in 10% formalin and embedded in paraffin. From each biopsy sample, 6 slices were serially cut into 5 µm thick sections (3 for assessing 8-OHdG-positive area via immunohistochemical examination; 3 for assessing fibrosis area via Azan staining). Immunoenzymatic staining was performed using a DAKO LSAB System (DakoCytomation, Kyoto, Japan) according to the manufacturer's instructions but with a slight modification, as described previously. 10 Cardiac sections embedded in paraffin were preincubated with 1.5% hydrogen peroxide and normal bovine serum albumin to block nonspecific reactions. Then, these samples were treated by microwaving for 1 minute. Mouse monoclonal anti-8-OHdG antibody (N45.1) (1:300 dilution; Japan Institute for the Control of Aging, Fukuroi, Japan) was added, and the sections were incubated at 4°C overnight. As a negative control, mouse monoclonal IgG antibody (1:50 dilution; DakoCytomation) was used. The sections were then incubated with biotinylated anti-mouse immunoglobulin for 20 minutes and subsequently with horseradish peroxidase-labeled streptavidin solution for 30 s. The slides were rinsed in cold Tris-buffered saline after each step of incubation. Peroxidase activity was visualized with diaminobenzidine tetrahydrochloride solution. Finally, hematoxylin staining was performed to confirm the cytosol and nuclei of cardiomyocytes. As normal controls, we used 9 endomyocardial LV biopsy samples taken from 3 patients with idiopathic VT but normal LV function. Similarly, transbronchial lung biopsy samples in 3 patients with pulmonary sarcoidosis were used as inflammatory controls. All procedures were performed under the same conditions described above.
In parallel, samples from each of the 3 different biopsy areas were fixed immediately in 10% buffered formalin, embedded in paraffin, routinely processed, and stained with azan to observe the contrast between myocardium and fibrosis.
For each patient, at least 30 digital images at 100× and 200× magnification were acquired from the biopsy samples for each analysis (immunohistochemical examination and azan staining), with subendocardial and perivascular areas excluded from further analysis. An automated image analysis protocol (using an ImageJ macro 17 ) was applied to determine the immunohistochemical-positive area of cardiac tissue expressed as (immunohistochemical-positive area/total area)×100, and myocardial fibrosis area expressed as (myocardial fibrosis area/total area)×100.
Statistical Analyses
All results are expressed as mean±SD. Categorical variables are presented using frequency counts, and intergroup comparisons such as sex and treatment were analyzed using the χ 2 test. Comparisons between 2 groups were performed using the Mann-Whitney test. The Mann-Whitney method with Bonferroni correction was used for comparisons among ≥3 groups. After Bonferroni correction, P values remained <0.005 for multiple comparisons of U-8-OHdG levels, immunohistochemical-positive area, and myocardial fibrosis area among 5 groups, and P values <0.017 were obtained for multiple comparisons of U-8-OHdG levels among 3 groups. The correlations between U-8-OHdG levels and immunohistochemical-positive area of cardiac tissue or cardiac fibrosis area were analyzed using Spearman rank correlation coefficient. Logistic regression analysis was performed for determinant factors associated with VT in patients with active CS. The cutoff level was defined by the point of maximum sensitivity plus specificity on receiver operating characteristic curve analysis showing the association of VT with U-8-OHdG. All analyses were performed using SPSS version 19 (SPSS Inc, Chicago, IL). P<0.05 were considered to indicate statistical significance.
Results
Baseline Patient Characteristics
Sixty-two patients diagnosed with CS were defined as having nonactive CS (n=26) or active CS (n=36) according to the absence or presence of abnormal 18 F-FDG accumulation in cardiac tissues, respectively. Furthermore, active CS patients were divided into a CS-VT group (n=18) and a CS-nVT group (n=18). Table II in the Data Supplement shows the clinical information of the 36 active patients with CS. CS was diagnosed in all patients according to the Japanese guideline for CS (Table I in the Data Supplement). On analyzing the patterns of FDG accumulation in the 36 patients with active CS, there was no difference in U-8-OHdG levels between patients with FDG accumulation in the heart (n=15; 19.7±7.2 ng/ mg·Cr) and those with FDG accumulation in the heart and another organ (n=21; 19.3±7.2 ng/mg·Cr; Table II in the Data Supplement). Table 1 shows the baseline patient characteristics of the 36 patients with active CS, 26 patients with nonactive CS, and 27 matched patients with DCM serving as HF controls. Although there were no differences in sex, age, body surface area, New York Heart Association classification, LV The normal range of the U-8-OHdG level is <10 ng/mg·Cr, as taken from a previous study. 8 BNP indicates brain natriuretic peptide; BSA, body surface area; BUN, blood urea nitrogen; CRP, C-reactive protein; CS, cardiac sarcoidosis; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; IL-6, interleukin 6; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; T-bil, total bilirubin; TNF-α, tumor necrosis factor-α; TnT, troponin T; U-8-ISO, urinary 8-isoprostane; U-8-OHdG, urinary 8-hydroxy-2′-deoxyguanosine; and UA, uric acid. Oxidative Stress and Ventricular Arrhythmia in CS end-diastolic diameter (LVDd), LV ejection fraction (LVEF), systolic blood pressure, heart rate, brain natriuretic peptide, urinary 8-isoprostane, uric acid, CRP (C-reactive protein), tumor necrosis factor-α, IL-6 (interleukin 6), total bilirubin, blood urea nitrogen, estimated glomerular filtration rate, or TnT (troponin T); only U-8-OHdG levels were significantly higher in the active CS group than in the DCM group (P<0.0001). Table 2 shows the comparison of patient characteristics between the CS-VT and CS-nVT groups. LVDd, brain natriuretic peptide, U-8-OHdG, and TnT were significantly higher in the CS-VT group than in the CS-nVT group, and episodes of premature ventricular contraction/nonsustained VT were significantly more frequent in the CS-VT group than in the CS-nVT group. There were no differences in other markers, other symptoms, or treatments between the CS-VT and CS-nVT groups. Figure 2 shows U-8-OHdG levels in the CS-VT, CS-nVT, nonactive CS, DCM, and control groups. U-8-OHdG was significantly higher in active CS (both for CS-VT and CSnVT) than in nonactive CS, DCM, and controls. Furthermore, U-8-OHdG levels were significantly higher in CS-VT than in CS-nVT (24.6±7.1 versus 15.2±3.8 ng/mg·Cr; P<0.0001), irrespective of the indices of cardiac function.
Comparison of U-8-OHdG Levels Across the Active CS-VT, Active CS-nVT, Nonactive CS, DCM, and Control Groups
Histological Assessment of Inflammation and Fibrosis in Heart Tissue Samples Obtained From Endomyocardial Biopsy Across the Active CS-VT, Active CS-nVT, Nonactive CS, DCM, and Control Groups
Immunohistochemical examination of LV biopsy samples using anti-8-OHdG antibody revealed that the positive 8-OHdG staining area of cardiac tissue was significantly greater in CS-VT than in CS-nVT, nonactive CS, and DCM ( Figure 3A) , and that U-8-OHdG was significantly correlated with immunohistochemical-positive area (Figure 3B ; n=58; R=0.61; P<0.0001). Histological examination with azan staining also showed that fibrosis area in cardiac tissue was significantly larger in CS-VT than in controls or DCM ( Figure 3C ), and that U-8-OHdG was significantly correlated with myocardial fibrosis area (Figure 3D; n=58; 
R=0.46; P<0.0001).
Furthermore, to confirm the immunohistochemical results, we examined the relationship between immunohistochemicalpositive area and the difference between coronary sinus and aortic serum 8-OHdG levels (A-V step-up). The immunohistochemical-positive area was positively correlated with the A-V step-up (n=31; P<0.01; r=0.49), and the A-V step-up was significantly correlated with U-8-OHdG levels (n=31; P<0.01; r=0.48). These findings suggest that U-8-OHdG levels also reflect myocardial oxidative stress and are mainly derived from cardiac tissue.
In patients with immunohistochemical-positive endomyocardial biopsy (n=24), immunohistochemical-positive area did not correlate with SUVmax on 18 F-FDG-PET (P=0.31), 18 F-FDG-PET (P=0.91), or regional wall motion abnormality score on echocardiography (P=0.08), which was used as an index of myocardial scar. Table 3 shows the outcomes of the univariate and multivariate analyses of factors associated with sustained VT in patients with active CS. Univariate analysis was performed for 13 variables (age, sex, body surface area, New York Heart Association class, LVDd, LVEF, estimated glomerular filtration rate, U-8-OHdG, brain natriuretic peptide, CRP, IL-6, SUVmax, SUV>50%, and regional wall motion abnormality score), of which 9 were entered into the multivariate analysis (age, sex, New York Heart Association class, LVEF, U-8-OHdG, brain natriuretic peptide, SUVmax, SUV>50%, and regional wall motion abnormality score) using the stepwise downward method to identify determinant factors of VT. Finally, U-8-OHdG remained a determinant factor of VT (odds ratio, 1.71; 95% confidence interval, 1.056-2.7548; P=0.02).
Univariate and Multivariate Analyses of Determinant Factors Associated With VT in Patients With Active CS
Determination of the Optimal Cutoff Value of U-8-OHdG as a Determinant Factor of VT in Patients With Active CS
Receiver operating characteristic analysis for the identification of patients with VT revealed the cutoff value of U-8-OHdG was 17.5 ng/mg·Cr (sensitivity, 89%; specificity, 83%; area under the curve, 0.90; Figure 4 ).
Patient Characteristics and Immunohistochemical Assessment of 8-OHdG in Transbronchial Lung Biopsy Samples in Patients With Pulmonary Sarcoidosis
The characteristics of the 9 patients with pulmonary sarcoidosis are listed in Table III in the Data Supplement. Patients number 1 to 9 were diagnosed with pulmonary sarcoidosis according to the World Association of Sarcoidosis and Other Granulomatous Disorders guideline, 18 but they were not diagnosed with CS because they did not fulfill the Japanese Ministry of Health and Welfare guideline (Table I in the Data Supplement). 14,15 Patients number 1 to 6 had accumulation of 18 F-FDG only in the lungs, whereas patients number 7, 8, and 9 had accumulation of 18 F-FDG in both the lungs and heart, and their U-8-OHdG levels (14.7, 12.6, and 13.3 ng/mg·Cr, respectively) tended to be higher than the values noted in patients with no 18 F-FDG accumulation in the heart (patients number 1 to 6); patients number 7, 8, and 9 also had ECG abnormality (premature ventricular contraction, complete right bundle branch block, left anterior fascicular block; Numeric data are expressed as mean±SD. The normal range of U-8-OHdG was defined as <10 ng/mg·Cr, as taken from a previous study. 8 ACE indicates angiotensin-converting enzyme; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; AVB, atrioventricular block; BNP, brain natriuretic peptide; BSA, body surface area; BUN, blood urea nitrogen; CRP, C-reactive protein; CRT-D, cardiac resynchronization therapy defibrillator; CS, cardiac sarcoidosis; CS-nVT, cardiac sarcoidosis without ventricular tachycardia; CS-VT, cardiac sarcoidosis with ventricular tachycardia; DDD-PM, DDD pacemaker; eGFR, estimated glomerular filtration rate; fibrosis area, area of fibrosis on azan staining; HF, heart failure; ICD, implantable cardioverter-defibrillator; IHC-positive area, area of positive 8-OHdG staining on immunohistochemical assay of myocardium tissue; IL-6, interleukin 6; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PVC/NSVT, premature ventricular contraction/nonsustained ventricular tachycardia; RWMA, regional wall motional abnormality; SBP, systolic blood pressure; SUV>50%, the proportion of pixels with SUV above the cutoff of 50% of SUVmax of the whole pixels; SUVmax, maximum standardized uptake value; T-bil, total bilirubin; TNF-α, tumor necrosis factor-α; TnT, troponin T; U-8-ISO, urinary 8-isoprostane U-8-OHdG, urinary 8-hydroxy-2′-deoxyguanosine; and UA, uric acid. F-FDG accumulation on PET/CT in the hilar lymph nodes and mediastinal lymph nodes, but not in cardiac tissues in cases 1, 2, and 3 ( Figure 5A ). U-8-OHdG levels were significantly lower in patients with pulmonary sarcoidosis (no CS) than in patients with CS ( Figure 5B ).
Discussion
General Overview
The most important finding of the present study is that U-8-OHdG, as a myocardial oxidative stress marker, was strongly associated with the occurrence of VT in patients with active CS. This conclusion is supported by the following findings. (1) On immunohistochemical examination, the 8-OHdG-positive area in heart tissue was significantly larger in patients with CS-VT than in those with CS-nVT or DCM. (2) Similarly, the 8-OHdGpositive area in heart tissue was significantly correlated with levels of U-8-OHdG, and the levels of U-8-OHdG were highest in CS-VT, followed by CS-nVT and DCM. (3) Multivariate analysis identified U-8-OHdG as an independent determinant for VT. (4) Receiver operating characteristic analysis demonstrated that the U-8-OHdG cutoff level of ≥17.5 ng/mg·Cr could identify patients with VT with a sensitivity of 89%, specificity of 83%, and area under the curve of 0.90. (5) In comparing U-8-OHdG levels and the number of VT episodes before and after corticosteroid therapy for VT, the number of VT episodes decreased in parallel with U-8-OHdG levels.
One important difference between active CS and DCM (HF controls) may be increased myocardial oxidative stress (Figure 3 ). This result is consistent with our previous findings. 10, 11 In addition, the present study indicates that immunohistochemical evaluations using anti-8-OHdG antibody support the hypothesis that myocardial oxidative stress related to inflammation strongly contributes to pathophysiology in patients with CS. There are several possible reasons why myocardial oxidative stress was associated with the occurrence of VT. First, myocardial ROS are associated with intracellular Ca 2+ handling disturbances under pathophysiological conditions via the following molecular mechanisms. [19] [20] [21] [22] Excess myocardial ROS cause oxidation of the cardiac ryanodine receptor [19] [20] [21] [22] and subsequent increases in diastolic Ca 2+ release, which in turn cause intracellular Ca 2+ overload. The intracellular Ca 2+ overload damages mitochondria, resulting in increased mitochondrial ROS production. 19, 20 Thus, the interaction between myocardial ROS and intracellular Ca 2+ handling elicits a vicious cycle of mitochondrial ROS production and diastolic Ca 2+ release. Second, intracellular Ca 2+ overload causes inward Na + current via Na + /Ca 2+ exchange, causing membrane potential to fluctuate in the phenomenon of delayed afterdepolarization. 23, 24 On overshooting the threshold, complete depolarizationinduced ventricular arrhythmia occurs. Sometimes, delayed potential because of tissue damage, for example, fibrosis, can result in sustained VT. Third, cardiac CS is characterized histologically by cardiac fibrosis. 11, 25, 26 In the present study, the extent of fibrosis in the heart was largest in the CS-VT group among all groups analyzed. Therefore, the occurrence of ventricular arrhythmia via a mechanism of triggered activity because of ROS-induced aberrant Ca 2+ release through ryanodine receptor may be sustained by the reentrant circuit created by fibrosis. Fourth, with regard to the issue of whether the increase of U-8-OHdG is the result or the cause of VT, inflammation-induced myocardial oxidative stress might have contributed to VT, because the total number of VT episodes decreased in parallel with U-8-OHdG levels after corticosteroid treatment in patients with active CS ( Figure IA and IB in the Data Supplement).
U-8-OHdG as an Oxidative Stress Marker Is, to a Large Extent, Specific to Oxidized Cardiac Tissue
U-8-OHdG levels may be influenced by inflammation in systemic organs. However, U-8-OHdG levels in active CS were higher than those in active pulmonary CS and not affected by FDG accumulation in other organs ( Figure 5 ; Tables II  and III in the Data Supplement). These findings suggest that U-8-OHdG is a clinically useful marker for CS. Moreover, immunohistochemical-positive area was positively correlated with the A-V step-up, and the A-V step-up was significantly correlated with U-8-OHdG levels. One possible explanation why U-8-OHdG is mainly derived from cardiac tissue is that mitochondria are richest in cardiac myocytes, and therefore the effect of pathophysiological conditions on mitochondrial ROS generation is larger in heart tissue. 8, 9, 11, 12, 23 These results suggest that U-8-OHdG is an alternative, easy-to-measure myocardial oxidative marker, although histological examination of endomyocardial biopsy remains important for the diagnosis of CS.
Limitations
The present study has several imitations. First, the cohort analyzed to identify the determinant factors of VT was small (n=36). Factors other than oxidative stress (eg, myocardial scar) are likely involved in VT. Further studies with larger BNP indicates brain natriuretic peptide; CI, confidence interval; CRP, C-reactive protein; eGFR; estimated glomerular filtration rate; IL-6, interleukin 6; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association class; OR, odds ratio; RWMA, regional wall motional abnormality; SUV>50%, standardized uptake value over 50% of the maximum; SUVmax, maximal standardized uptake value; and U-8-OHdG, urinary 8-hydroxy-2′-deoxyguanosine. sample size are warranted to confirm the relation between oxidative stress and VT. Second, because the heart may not be the only source of U-8-OHdG, the specificity of this biomarker to distinguish myocardial from extracardiac inflammation is limited. In clinical settings, however, U-8-OHdG may be useful for evaluations of the diagnosis, treatment, and pathophysiology of CS judging from serological and immunohistochemical examinations. Third, we performed endomyocardial biopsy in only 24 of 36 patients with active CS because of the risks involved with the procedure. Therefore, there is the possibility of selection bias. Fourth, only 3 endomyocardial biopsy samples were obtained in each patient, which may not represent the status of the endomyocardial tissue (and thus the extent of oxidative stress and fibrosis) in the whole heart. Fifth, in our study, patients diagnosed as having CS according to the Japanese Ministry of Health and Welfare criteria but with no abnormal isotope accumulation in the heart by PET or Ga scintigraphy ( Figure 1 ) were defined as having nonactive CS. As such patients may not be truly CS patients, the data for the nonactive CS group was excluded from multivariate analysis for VT.
Conclusions
These findings suggest that U-8-OHdG level, which represents myocardial oxidative stress, was associated with sustained VT in patients with active CS diagnosed by 18 F-FDG-PET.
Therefore, U-8-OHdG may provide additive and relevant information about the arrhythmic substrate. F-FDG PET/CT revealed 18 F-FDG accumulation in hilar lymph nodes and mediastinal lymph nodes, but not in cardiac tissues in cases 1, 2, and 3. Histological and IHC examinations in lung tissue revealed that staining with anti-8-OHdG antibody was negative despite the presence of noncaseous epithelioid cell granuloma on hematoxylin-eosin (HE) staining in cases 1 and 3. B, U-8-OHdG levels were significantly lower in patients with pulmonary sarcoidosis (but no cardiac sarcoidosis) than in patients with cardiac sarcoidosis. †P<0.0001 vs control. ‡P<0.0001 vs pulmonary sarcoidosis.
